Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAN2401 phase 2 dose-regimen finding study in early Alzheimer's disease
2012-002843-11Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing BAN2401 with Placebo (2 arms). Primary endpoint: Change from baseline in the derived Composite Clinical Score. Started Mar 2013; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2012-002843-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002843-11.